Targeting of Aberrant avß6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. (2017)
Attributed to:
King's Health Partners Confidence in Concept
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ymthe.2017.09.018
PubMed Identifier: 28958577
Publication URI: http://europepmc.org/abstract/MED/28958577
Type: Journal Article/Review
Volume: 25
Parent Publication: Molecular therapy : the journal of the American Society of Gene Therapy
Issue: 10
ISSN: 1525-0016